Stocklytics score rationale: value 56, quality 32, growth 50.
Financials
2020
2021
2022
2023
2024
2025
0
0
102694000
14090000
45563000
22503000
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also…
Forecast
Consensus Buy from 16 analysts. Average price target $51.33, +148.1% versus the current price. Low $45.00. High $58.00.
Analysts have an average 12-month price target of $51.33 for NewAmsterdam Pharma Company (NAMS), 148.1% above the current price of $20.69. Of 16 analysts covering the stock, 15 rate it Buy or Strong Buy, 1 Hold, and 0 Sell or Strong Sell, giving a consensus of Buy.
Forecasts are third-party estimates and often wrong. They are not investment advice.
NAMS price target
12-month price target
Low
$45.00
Average
$51.33
High
$58.00
The average is 148.1% above the current price of $20.69.
Is NewAmsterdam Pharma Company a buy or sell?
Of 16 analysts, 15 rate NewAmsterdam Pharma Company Buy or Strong Buy, 1 Hold, and 0 Sell or Strong Sell. The consensus label is Buy. That split is not a recommendation.
NewAmsterdam Pharma Company earnings and revenue forecast
The Stocklytics Score for NAMS is 46 out of 100. It averages value, quality, and growth against a large-cap US universe. It is not a price target and not a buy or sell rating. Fair value is a separate estimate on the fair value tab.
NAMS forecast FAQs
What is the NAMS price target?
$51.33 average, with a published range of $45.00 to $58.00.
Is NewAmsterdam Pharma Company a buy or sell?
The consensus is Buy from 16 analysts. This is not a recommendation.
What is the NewAmsterdam Pharma Company stock forecast for 2026?
Analysts' average EPS estimate for 2026 on file is -1.89. The average revenue estimate is $30.26 million.
What will NAMS be worth in 2030?
No reliable forecast exists that far out.
When is NewAmsterdam Pharma Company's next earnings report?
The next earnings date is shown on the stock page when a future report is on the calendar. This forecast does not invent a date.
Capital is at risk. Stocklytics is operated by Stocklytics Inc., a Marshall Islands company. It is not regulated by the FCA and does not give investment advice.